// App-Quantinova.ai

1896 : ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Researchers

Presenter

  • Alan S. Wayne

Principal Investigators

  • Gerard Michel

  • Daniel W. Lee

  • Andr Baruchel

  • Sonali Chaudhury

  • Patrick A. Brown

  • Michelle Hermiston

  • Joerg Krueger

  • Tong Shen

  • Kristy Tailford

  • Behzad Kharabi Masouleh

Medical Centers

  • Children's Hosp Los Angeles, Los Angeles, CA

  • Hopital pour Enfants de La Timone, Marseille, France

  • University of Virgina, Charlottesville, VA

  • hematology and immunology department, Robert Debré Hospital, GH APHP Nord Université de Paris, Paris, France

  • Lurie Children's Hospital, Chicago, IL

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Department of Pediatrics (Pediatric Hematology/Oncology), University of California San Francisco, San Francisco, CA

  • Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • Kite, a Gilead company, Santa Monica, CA

Locations

  • United States

  • France

  • Canada

Companies

  • Kite Pharma, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Burkitt lymphoma

  • Lymphomas

  • Diffuse large B-cell lymphoma

Biomarkers

  • Breakpoint Cluster Region

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Blinatumomab

  • fludarabine tablet

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT02625480

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved